These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9056592)

  • 21. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
    Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
    Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers.
    Piñeyro-López A; Piñeyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez-Silva M; Waksman N; E Salazar-Leal M; Luján-Rangel R
    Clin Ther; 2007 Sep; 29(9):2049-54. PubMed ID: 18035203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal sampling times in bioequivalence tests.
    Kong FH; Gonin R
    J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
    Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
    Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment.
    Tamimi JJ; Salem II; Mahmood Alam S; Zaman Q; Dham R
    Biopharm Drug Dispos; 2005 Jul; 26(5):205-10. PubMed ID: 15906418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New approach to assess bioequivalence parameters using generalized gamma mixed-effect model (model-based asymptotic bioequivalence test).
    Chen YI; Huang CS
    Stat Med; 2014 Feb; 33(5):786-97. PubMed ID: 24105871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On confidence limits associated with Chow and Shao's joint confidence region approach for assessment of bioequivalence.
    Hsu HC; Lu HL
    J Biopharm Stat; 1997 Mar; 7(1):125-34. PubMed ID: 9056593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of outlying subjects on decision of bioequivalence.
    Ki FY; Liu JP; Wang W; Chow SC
    J Biopharm Stat; 1995 Mar; 5(1):71-94. PubMed ID: 7613561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The assessment of individual and population bioequivalence.
    Chinchilli VM
    J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Applying multilevel models in evaluation of bioequivalence (I)].
    Liu QL; Shen ZZ; Chen F; Li XS; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An adjusted two one-sided t-test for the assessment of bioequivalence with multiple doses.
    Wang W; Hsuan F; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):157-70. PubMed ID: 9056595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discussion of individual bioequivalence by M.-L. Chen.
    Gould AL
    J Biopharm Stat; 1997 Mar; 7(1):23-9. PubMed ID: 9056584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Robustness of bioequivalence procedures under Box-Cox alternatives.
    Xiao W; Barron AM; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):135-55. PubMed ID: 9056594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Residuals and outliers in replicate design crossover studies.
    Schall R; Endrenyi L; Ring A
    J Biopharm Stat; 2010 Jul; 20(4):835-49. PubMed ID: 20496209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence analysis on crossover design experiment in bioequivalence studies.
    Huang Y; Ke BS
    Pharm Stat; 2014; 13(2):110-8. PubMed ID: 24338978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A practical approach for the assessment of bioequivalence under selected higher-order cross-over designs.
    Vuorinen J
    Stat Med; 1997 Oct; 16(19):2229-43. PubMed ID: 9330430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal adaptive sequential designs for crossover bioequivalence studies.
    Xu J; Audet C; DiLiberti CE; Hauck WW; Montague TH; Parr AF; Potvin D; Schuirmann DJ
    Pharm Stat; 2016; 15(1):15-27. PubMed ID: 26538182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.